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The parents of a 3-year old boy are anxious about their son who has recurring episodes of wheezing. They are frustrated that no
one seems to be able to give them answers to their questions and would like a referral to a specialist. Does their son have asthma
and what is the prognosis; how can the recurrent wheezing be managed and can the risk of asthma be reduced; are there lifestyle
changes that could improve the environment and avoid triggers? Communication and support from the family practice team were
essential. Listening to the parents’ concerns, explaining the diagnostic uncertainty, being realistic about what drug treatments
could achieve, and providing practical advice on inhaler use and trigger avoidance reassured the parents that there was a strategy
for managing their son’s wheeze. The specialist referral was postponed.
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Case study
● The parents of a 3 year old boy have come to see their family
doctor about their son whose recurrent episodes of wheeze
and respiratory symptoms are causing concern. They are
frustrated that no-one seems able to give them a clear
diagnosis, and worried because the treatment they have been
given is not controlling his symptoms. They would like a
referral to a specialist to see if they can get some answers.
● Looking back through the records, the first episode of wheeze
was at the age of 6 months. This was diagnosed as
bronchiolitis and resulted in a brief admission. He had one
further admission the following winter that was labelled as
‘viral associated wheeze’, and two subsequent attendances at
the emergency department, on the last occasion being told
that he had ‘asthma’. In addition there are six primary care
consultations for ‘wheeze’ or ‘chest infections’. These episodes
have been variously treated with bronchodilators, steroids
(inhaled and oral) and/or antibiotics—none of which have had
any convincing effect.
● He was a normal full term delivery and thrived well from birth.
Mother had hay fever as a teenager, and father smokes
(though ‘never in the house’)
A clinical case, such as this 3-year old boy with recurrent
wheeze, raises many questions that need to be explored in order
to address parental concerns and manage the child’s condition.
The boy is thriving, height and weight just above the 50th centile.
WHY DO THE PARENTS REQUEST A REFERRAL?
A host of reasons may underpin the parent’s request. Is their
concern that the wheezy episodes are harmful? Are they unable to
sleep because the child is disturbed at night? Is it the lack of a clear
diagnosis and uncertainty about the boy’s long-term prognosis
that is causing the worry? Do the parents want advice on avoiding
triggers or information on what to do when the wheezing recurs,
or is the main focus of this consultation the (perceived) additional
value of a referral to a specialist? Or all of these?
DOES OUR SON HAVE ASTHMA, AND WHAT IS THE
PROGNOSIS?
Wheezing is common in young children
Wheezing in children under 3 years of age is common. By
30 months, 26% of children in a UK birth cohort (ALSPAC,
Avon longitudinal study of parents and children) had wheezed in
the previous 12 months.1 Wheezing, as in this case, is often not
just a minor inconvenience. Data from the latest British Thoracic
Society national paediatric audit of wheezing/asthma showed that
24% of all the children admitted to hospital were between 12 and
24 months, boys outnumbering girls in a ratio of nearly 2 to 1.2
Longitudinal birth cohort studies have transformed our under-
standing of wheezing in early childhood,3 demonstrating that the
origins of most asthma lie in early childhood and that variations in
the natural history of childhood wheezing are associated with
different long-term outcomes. Between 4–6 of these ‘phenotypes’
have been identified.4, 5 One major group is transient early
wheezers whose symptoms remit by the time the child is school
age. The absence of atopy is, at present, the best marker for this
group.5 Early onset of wheezing is associated with lower lung
function at adolescence and the presence of atopy is associated
with persisting asthma.4 However, at present, it is not possible to
assign a particular phenotype to an individual child to determine
either treatment or prognosis; indeed, it is common for the
features to change during early childhood.5 A summary of the
recent evolution of the terminology of 'asthma' in children is given
in Table 1.
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Defining ‘wheeze’ is not always simple
Wheezing is usually associated with airflow obstruction and is
central to the diagnosis of asthma. In older children, airflow
obstruction and reversibility can be documented objectively on
spirometry or peak flow measurements, but lung function
measurements in children younger than 4–5 years are usually
not feasible in clinical practice. This places much greater emphasis
on the history of wheezing provided by the parents/caregivers,
which is problematic because what parents and doctors mean by
‘wheezing’ is often very different.6, 7 (See Table 2). Furthermore,
the word ‘wheeze’ does not exist in some languages. Because of
this most guidelines emphasise that if a doctor hears wheezing on
auscultation, it is an important observation to record.
All that wheezes is not asthma
Not all wheezing is due to asthma or viral infections. There are rare
but important differential diagnoses.8 Persistent wheezing in
young children, wet cough, vomiting, failure to thrive and a poor
response to anti-asthma medications may be important clues to
alternative diagnoses such as cystic fibrosis.
Viral wheezing and asthma
Viruses have been found in at least 80% of wheezing episodes in
children.9 With the exception of respiratory syncytial virus (RSV) in
infants hospitalised with bronchiolitis, human rhinovirus (HRV) is
by far the most common virus isolated in children over
12 months.10 HRV-C is the most common rhinovirus species in
wheezing children, and, compared to other viruses, is more often
associated with recurrent acute wheezing attacks severe enough
to result in children presenting to hospital.11 In the follow up of a
high-risk birth cohort (one parent with positive skin prick test to
an aeroallergen and/or asthma) the persistence of asthma at age
13 years was most strongly associated with rhinovirus-associated
wheezing illnesses and with aero-allergen sensitisation in early
life.12 Evidence suggests that some children are more susceptible
and have more severe rhinovirus infections because of a subtle
defect in innate anti-viral immunity.13
Bronchiolitis and the link with asthma
In the first year of life, bronchiolitis (usually defined as the first
episode of wheezing in children less than 2 years old)14 due to RSV
infection is the commonest lower respiratory tract illness with
wheezing, affecting around 1 in 3 children.15 On auscultation
there is wheezing and/or fine crackles. The disease is usually mild
with only 2–3% of children being hospitalised.14
An association between bronchiolitis and asthma has been
noted in many studies. However, while longitudinal follow-up
suggests that RSV infections in early childhood are associated with
an increased risk of wheezing, this association subsides with age
and becomes insignificant by 13 years, unlike rhinovirus infections
where the association with wheezing persists.16
Table 1. Asthma: What’s in a name?
Historically, there has been a reluctance to diagnose asthma in children. In 1983, Speight et al., highlighted that children who were not given a
diagnosis of asthma were not treated appropriately and suffered unnecessary morbidity.i Fears that the label of ‘asthma’ might cause distress were
unfounded; parents were ‘uniformly relieved’ that the cause of their child’s symptoms had been identified. There followed a drive to reduce under-
diagnosis and under-treatment, though the status of wheezy infants (under 1 year of age) remained contentious.ii, =iii Studies of the natural history of
asthma in children,iv however, began to define phenotypes of ‘transient early wheezers’, ‘late-onset wheezers’ and ‘persistent wheezing’ which
seemed to contradict the drive to ‘encourage healthcare professionals to make a positive diagnosis of asthma whenever recurrent wheezing,
breathlessness and cough occur’,iii by suggesting that only a minority of wheezy toddlers would prove to have persistent asthma. The concern now
was over-diagnosis and over-treatment of young children with guidelines highlighting the ‘difficulty of making a confident diagnosis of asthma in
young children’.v
In some healthcare contexts under-diagnosis of asthma remains a problem, as respiratory symptoms are routinely labelled (and treated) as
pneumonia,vi or described symptomatically to avoid the perceived stigma of the label ‘asthma’.
This case study has adopted a pragmatic approach, sharing uncertainties of diagnosis and prognosis with the parents, objectively monitoring trials of
treatment so that symptoms that can be treated are relieved, a strategy that resonates with the contemporary approach of ‘treatable traits’.vii
i. Speight, A. N. P., Lee, D. A., & Hey, E. N. Underdiagnosis and undertreatment of asthma in childhood. BMJ 286, 1253–1256 (1983).
ii. British Thoracic Society. The British guidelines on asthma management. Thorax 52 (Suppl. 1), 1–21 (1997).
iii. Global Initiative for Asthma. Global strategy for asthma management and prevention. GINA (1995) Diagnosis: pp 47–61
iv. Martinez, F.D., Wright, A.L., Taussig, L.M., Holberg, C.J., Halonen, M., & W.J. Morgan. Asthma and wheezing in the first six years of life. The Group
Health Medical Associates. N. Engl. J. Med. 332, 133–138 (1995).
v. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention, 2016. Available from www.ginasthma.org. Accessed July 2016
vi. Nantanda, R., Tumwine, J. K., Ndeezi, G., & Ostergaard, M. S., Asthma and Pneumonia among children less than five years in Mulago hospital
Uganda: evidence of under-diagnosis of asthma. PLoS One 8, e81562 (2013).
vii. Agusti, A., Bel, E., Thomas, M., Vogelmeier, C., Brusselle, G., Holgate, S., et al. Treatable traits: toward precision medicine of chronic airway diseases.
Eur. Respir. J. 47, 410–419 (2016).
Table 2. Parents interpretation of children’s respiratory symptoms.6
A study in the East end of London, invited parents (first language English, Urdu, Bengali (Sylheti), or Turkish) to view a video of children’s respiratory
symptoms:
• A third of parents use other words for wheeze; a third falsely label other sounds as wheeze
• Compared to other respiratory sounds, parents are more likely to label wheeze correctly
• Parents are better able to locate sounds than to label them
• There was no significant difference between parents of wheezers and non-wheezers in accuracy of labelling of location
• Parents are better at labelling if English is their first language
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Will symptoms persist in the long term (the prognosis)?
For some children, early wheezing will translate into long-term
asthma. This is particularly the case for those with early rhinovirus
infections, with sensitisation to aeroallergens and with reduced
lung function. The problem is that we cannot, with complete
certainty, identify those in whom symptoms will persist and those
in whom they will remit. Nevertheless, in the child in our case
study, the early frequent and severe episodes in a child with a
maternal history of hay fever and possible exposure to environ-
mental smoke may point to a more protracted course of the
respiratory symptoms.
Although not widely used in clinical practice, several asthma
prediction scores have been developed and published in the last
decade,17 and may usefully inform the history that the healthcare
professional needs to take. The clinical asthma prediction score
(CAPS), designed specifically for use in general practice, is based
on five parameters: age, family history of asthma or allergy,
wheezing-induced sleep disturbances, wheezing in the absence of
colds, and (if available) specific Immunoglobulin E.18 The score
ranges from 0 to 11 points; CAPS <3 signifies a negative predictive
value of 78% while CAPS ≥7 signifies a positive predictive value of
74%. Measurement of specific IgE provides additional value,
though the downside is the need for a blood test in a young child.
Prognosis for the 3 year old boy in the case study
Based on the available information, the score in this boy will be at
least three (asthma probability 30% at school age) but, with
additional information on specific IgE and sleep disturbances,
could be as high as nine (asthma probability of 82% at school
age). These CAPS scores suggest a policy of either watchful
waiting (asthma probability 30–60%) or initiating formal asthma
management (asthma probability of 60% or higher).18 The wide
range reflects the current difficulties in predicting prognosis.
WHAT TREATMENT WILL REDUCE OUR SON’S SYMPTOMS—
AND, IF POSSIBLE, PREVENT LONG-TERM ASTHMA?
At present, there is no treatment known to ‘cure’ asthma. Current
treatments, however, can control symptoms and modify the
chances of attacks.19, 20 Bronchodilators should be used when the
child is wheezy, though discussion with parents is important to
ensure they are interpreting sounds correctly and that the child
responds to the broncholdilator. If asthma is probable, inhaled
steroids are the most effective treatment for controlling symptoms
and should be first-line treatment if attacks are frequent and
severe and/or if there are interval symptoms. Perhaps the one
clear ‘fact’ is that complete avoidance of exposure to environ-
mental tobacco smoke is important.21
Does preventing RSV infection reduce risk of asthma?
Reflecting the observation that the persistence of wheezing
beyond childhood is associated with rhinovirus infection (as
opposed to RSV), prevention of RSV infection does not have a
measurable effect on subsequent episodes of wheeze and
asthma.22 Giving pre-term infants anti-RSV antibodies for the first
year of life reduces RSV infections but not recurrent wheeze over
the pre-school years.23
Does early start of inhaled steroids prevent risk of asthma?
In 2006 three studies were published on the use of inhaled
corticosteroids (ICS) in young children at high risk of developing
asthma with one or more episodes of wheeze.24–26 Although some
children had a temporary reduction in symptoms during ICS
treatment, this did not prevent development of asthma. So, in our
clinical case, it is important to discuss with the parents that the
early start of ICS is not needed as a primary prevention strategy
but it might have an effect on the severity of the symptoms.
Relief of acute wheezy episodes
Let us consider that the consultation for this boy and his parents
was triggered by a further attack of respiratory symptoms and
wheeze. If there are no alarming symptoms, such as respiratory
distress, requiring immediate intervention and/or referral, the use
of a short acting beta2 agonist (SABA) will be the drug of choice to
relieve the acute wheeze.8 Symptom relief is the main goal; SABA
do not alter the natural course of the wheezy episode.
SABA can be administered safely and effectively at all pre-
school ages, including below the age of one. Inhalation is well
tolerated and an effect can be expected within 10–15min. If
necessary, inhalation of SABA (with a face mask) during the
consultation may provide prompt relief of symptoms, demonstrat-
ing both how inhaled medication should be delivered by a spacer
(five breaths to one puff) and the rapid symptom response that
can result. A dose of a SABA may be needed every 3–6 hours for
one or more days until the symptoms of wheeze disappear.
It is essential to ask the parents to revisit your practice at the
end of the episode of respiratory symptoms (normally 1–2 weeks
after the first visit). During this review the effect of the medication
can be evaluated, and in case of complete remission of the
symptoms medication should be stopped in order to prevent
unnecessary use and overtreatment with SABA in the future.
Furthermore, the parents can be advised on when to visit the
practice again in case new symptoms appear.
Prevention in children with frequent wheezy episodes or a higher
probability of asthma
The indication for treatment with ICS (step 2 in GINA; see Fig. 1) is
based on the frequency and severity of symptoms, and the
probability that the child has asthma. The older the child, the
presence of a multiple trigger wheeze and the presence of a
positive specific IgE test to house dust mite, cat or dog allergens
(or a positive family history for asthma and /or allergy) will
increase the chances of a response to regular treatment with an
ICS.
Treatment with ICS should be started as a carefully monitored
diagnostic trial,27 and the clinical effect evaluated after
4–8 weeks.28 If the child responds well to a treatment with ICS,
it is recommended, in discussion with parents, to reduce and
ultimately withdraw the medication to exclude natural resolution
of symptoms. If symptoms recur during or after withdrawal, restart
treatment and consider on-going treatment.8, 29 If there is no
response to treatment, the ICS should be stopped and alternative
diagnoses should be reconsidered.
The use of ICS in children with viral induced episodes of
wheeze, without symptoms or triggers in between episodes, is
more controversial. The effect on symptoms is at best limited, but
a recent meta-analysis has shown that short-term (7–10 days) high
dose ICS, starting at the first sign of an URTI, may reduce the risk of
severe exacerbations.20
A follow-up consultation in general practice is essential when
inhalation medication is started in any child irrespective of the
indication. During this review, the parents can be informed about
the short and long-term prognosis and the action to take during a
subsequent episode. Prevention of overtreatment of children with
ICS and the (in)correct labelling of wheeze as asthma is as
important as overlooking an asthma diagnosis and not treating
with ICS. Until an asthma diagnosis is confirmed by a physician,
requests for repeat prescriptions of SABA or ICS in preschool
children should trigger a review of current status.
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Other medication that may be considered
Oral steroids during attacks do not seem to be effective in
preschool children with viral induced wheezing of moderate
severity.30, 31 They should be used only in children with severe
wheeze, and even then the evidence is not robust.19
A recent Cochrane review revealed no benefit from the use of
leukotriene receptor antagonists (LTRAs) in pre-school children
with viral induced wheeze. However, identifying these phenotypes
is challenging, and individual children may warrant a carefully
monitored trial of a LTRA.32 Long acting beta2-agonists (LABA)
have been studied in older children with persistent asthma as
add-on therapy to ICS. There are no studies on the use of LABA in
preschool children with recurrent wheeze and therefore their use
cannot be recommended.33
Management strategy in the 3 year old boy in the case study
In this particular case, the GP will need more than one review visit
before a clear clinical picture will emerge and before the parents
can be informed about the likely prognosis of the respiratory
symptoms in their child. The parents reported that inhaled
steroids did not have a convincing effect, but parental expecta-
tions need to be discussed (e.g. ICS will not reduce the frequency
of viral upper respiratory tract infections), and inhaler technique
and compliance with the trial of treatment needs to be checked
and discussed (see below). If the child is currently symptomatic a
further carefully monitored trial of ICS should be considered, if
they are asymptomatic a wait-and-see strategy may be appro-
priated. In either situation, even after reassurance of the parents
either by the General Practitioner (GP) and the practice nurse, a
referral to a specialist may sometimes be appropriate as the most
effective way to reassure the parents. Depending on resources in
primary care, however, a paediatrician may not have more
diagnostic or therapeutic possibilities in preschool children than
a general practitioner.
SUPPORTING WORRIED PARENTS
Diagnostic uncertainty & dealing with parental anxiety
It is recognised that approximately one in three children has at
least one episode of wheeze before their third birthday,1, 3 with
the expectation that the majority of children will outgrow their
symptoms between age 3 and 8 years.1, 3, 34, 35 This however
provides little comfort to a parent whose child is exhibiting
symptoms and experiencing exacerbations (see a perspective
from a parent in Table 3). It is important to explain that diagnosis
is based on the clinical history, symptoms and response to
treatment, and that these will need to be carefully observed and
re-considered over time.
Treatment has to be tailored to the individual child. Parental
acceptance that not all asthma therapies will prove effective in
reducing exacerbations can be hard to achieve. Explanations of
pharmacological treatment limitations may help to achieve more
realistic expectations. Some parents may need longer consulta-
tions or will benefit from a referral to other members of the
healthcare team such as the health visitor, asthma educator,
respiratory nurse, physiotherapist, or community health worker.
Education needs to be provided in plain language, using
pictures or models to illustrate, and tailored to the parents’
current understanding and beliefs. Parents may also benefit
from speaking to other parents who have been in a similar
situation and they may seek this type of support via social media
such as Facebook or Twitter. Parents should always be cautioned
Infrequent
viral wheezing 
and no or 
few interval 
symptoms
Symptom pattern consistent with asthma 
and asthma symptoms not well-controlled, or 
≥3 exacerbations per year 
Symptom pattern not consistent with asthma but 
wheezing episodes occur frequently, e.g. every 
6–8 weeks. 
Give diagnostic trial for 3 months.
Asthma diagnosis, and 
not well-controlled on 
low dose ICS
Not well-
controlled 
on double 
ICS
First check diagnosis, inhaler skills, 
adherence, exposures
CONSIDER 
THIS STEP FOR 
CHILDREN WITH:
RELIEVER
Other 
controller 
options
PREFERRED 
CONTROLLER 
CHOICE
As-needed short-acting beta2-agonist (all children) 
Leukotriene receptor antagonist (LTRA)
Intermittent ICS
Low dose ICS + LTRA Add LTRA 
Inc. ICS
frequency
Add intermitt ICS
Daily low dose ICS
Double 
‘ low dose’
ICS
Continue 
controller 
& refer for 
specialist 
assessment
STEP 1 STEP 2
STEP 3
STEP 4
Fig. 1 Stepwise approach to pharmacotherapy in children under 5 years. Reproduced with permission from the GINA guidelines.8
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about the use of less reputable sources of self-help and
encouraged to discuss strategies for self-management with their
own doctor or nurse. Table 4 lists some useful websites for
families.
Inhaler technique
The first experience of administering inhaled medication via a
spacer can have an impact upon the child’s acceptance of future
treatment. The spacer is often used for the first time when the
child is experiencing difficulty breathing. Having a facemask
placed over their nose and mouth can be frightening. Prior to first
use the child should have an opportunity to handle the spacer and
build up to the facemask being kept in position for up to 10 s
dependant on taught technique. Between wheezy episodes
parents should ensure their child remains familiar with the spacer
to try and avoid future distress. Although actively accepting an
inhaler should be the goal, administering treatment while a child
is sleeping is a practical strategy that may help in some situations.
Small children should never be chastised or wrapped in blankets
or towels to aid with inhaler administration and these methods
should be replaced with praise and distraction techniques.
Holding techniques should be demonstrated and parents should
be signposted to websites with demonstration videos as
reminders (for example: Asthma UK ‘Using your inhalers’ https://
www.asthma.org.uk/advice/inhalers-medicines-treatments/using-
inhalers). Inhalers (and spacers) should only be prescribed after
patients have received training in the use of the device and have
demonstrated satisfactory technique.27 If this is difficult in a time-
limited consultation, arrangements may be made with a local
community pharmacist, healthcare assistant, health educator or
practice nurse to check inhaler technique when inhalers have
been prescribed.
Self management
There is a paucity of evidence about effective self-management
strategies for parents of pre-school children.27 Parents often report
that their child’s condition seems to decline rapidly, but it is
important to discuss symptoms or behaviours exhibited in the day
(s) prior to previous exacerbations. On reflection, parents may be
able to identify non-specific signs (such as decreased dietary
intake, runny nose) as a precursor to an attack. Recognition of the
signs of increased work of breathing should be discussed with
parents and thresholds set for medical review. This may need to
be adapted dependant on family dynamics, geographical location
and severity of previous attacks. Safety is paramount and parents
should not be made to feel they are over reacting or seeking too
many medical reviews; they must feel confident to seek help at
crucial times.
CREATING A HEALTHY ENVIRONMENT
This is a 3-year old child with recurrent episodes of wheezing. The
health care professional has a responsibility to help parents create
a healthy environment by addressing any modifiable risk factors
such as tobacco and biomass smoke, in-door allergens, house
dampness and also to provide information about inevitable
respiratory viral triggers of asthma exacerbations.
Environmental risk factors for asthma exacerbations
The link between the environment and exacerbation of asthma
symptoms is a well-described entity.8 Many studies have
described the role of air pollutants (indoor and outdoor) including
biomass smoke and fumes from cars and factories, in triggering
asthma symptoms.36, 37 The effect of environmental tobacco
smoke, also known as second-hand smoking in causation
Table 3. Perspective from a parent
Getting a diagnosis
It started with bronchiolitis in autumn when my son was under 2 years old however he had subsequent wheezy episodes over winter and spring and
the diagnosis changed to viral induced wheeze. Depending on who we see, either in accident and emergency, GP practice or hospital consultant
some say he may have asthma and others say he is too young to have asthma. That has left us as parents frustrated. We have a family history of
asthma so it could be that.
Medications
When my son has a wheezy episode we have a plan to follow which was given to us by the respiratory nurse specialists at the hospital. It gives us
guidance on what to do when he gets a cold and when we need to see someone. Prednisolone seems to work but he has had so many courses over
the last year some of the doctors have started to admit him and monitor him instead without giving steroids.
Giving the inhaler through the spacer with mask has been challenging. Sometimes nurses don’t do it correctly or are in a rush to give all 10 puffs. This
has scared my son in the past but he got used to it over time. We know that if he is crying or upset he won’t get a full dose so it is important to keep
him calm. We learned some distraction techniques from the nurse specialists and they have been helpful.
Impact on family life
We have been to see our general practitioner, accident and emergency department, or hospital consultant on many occasions. The unpredictability of
the episodes has made it difficult for us to make family plans especially for a holiday. We ended up in hospital on two occasions when we were away
from home. We have had to take time off when he is unwell as he cannot go to nursery and this has had an impact on our jobs. Medical staff keep
saying it will get better as he gets older.
Table 4. Useful websites for families of wheezy children
Organisation Website Description
Asthma UK www.asthma.org.uk Advice and support parents need to help their child stay well with their
asthma
Chest Heart & Stroke Scotland. www.mylungsmylife.org Information, tips and advice to help parents make choices about their
child’s asthma
Children and Young Peoples Allergy
Network Scotland
www.cyans.org.uk The ‘families’ section gives basic information on the different types of
allergy and how to manage allergies
European Lung Foundation http://www.europeanlung.org Reliable information about a range of lung diseases and their risk factors
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and exacerbation of asthma symptoms in children is also well-
documented.38–40
Children exposed to environmental tobacco smoke, experience
more frequent and severe exacerbations of the asthma symptoms,
even where medical treatment is adequate.37, 40 The dust and
surfaces in a smoker’s home have been found to be contaminated
with tobacco smoke, even when parents avoid smoking in the
house.41 Vapour phase nicotine and particulates have been also
found in the home of smokers.42, 43 Generally, contamination and
exposure to second-hand smoke are 5–7 times higher in the
homes of ‘smoking outdoor’ people compared to non-smokers.41
Indoor air pollution, including use of biomass smoke from
burning wood, animal dung and crop residues for cooking and
heating, has been associated with an increased risk of asthma
exacerbations in children and adults.36 Therefore, improving air
quality at home and reviewing some of the activities that may
trigger attacks will be an important aspect of creating a health
environment for this child.
Besides air pollution, a consistent association of dampness with
respiratory symptoms is found among both atopic and non-atopic
children. House dust mite exposure and sensitisation may
contribute, but the link seems to be related principally to non-
atopic mechanisms.44 Moreover, indoor allergens from mouse,
cats, pets, dust mite and mould have been described as important
exposures that lead to exacerbation of asthma symptoms.44, 45
What can be done to create a healthy environment for this child?
As the diagnosis of asthma is increasingly likely, ICS along with
addressing modifiable environmental risk factors for exacerbations
(particularly tobacco smoke), can reduce hospital visits, avoid high
healthcare costs and improve quality of life of the child and his
parents.46, 47 The parents need to understand the benefits of the
lifestyle changes and should be motivated to creating a smoke-
free home, without exceptions for guests or friends.
Smoking cessation is a complex process and the parents will
need support from family, friends and the healthcare system to be
able to stop smoking. Key to this process is an understanding the
barriers to smoking cessation such as; parental beliefs about
second-hand smoke and readiness to quit smoking. Stress has
been described as a major barrier to quitting because cigarette
smoking is often used to give (temporary) relief from stress.48 It is
therefore important to discuss the sources of stress and coping
strategies that are not harmful. It is also important to build on
known motivators for smoking cessation including family support
and the will to protect the child from the effects of tobacco
smoke.49
Reduction in exposure to biomass smoke can be achieved
through use of alternative cooking and heating fuel such as
liquefied gas or by using improved cookstoves.50 However, the
challenges in adopting such changes including costs involved and
behavioural aspects must be discussed with the parents.51
Many children are sensitised to more than one allergen, and
many households have damp rooms. Reducing exposure to damp
and mould improves asthma control in adults, but the benefit of
interventions such as regular cleaning, avoiding use of carpets,
and withdrawing pets from the home,43 is described as ‘limited’ in
guidelines and can be ‘expensive and complicated’.8
The story continues…
● The family doctor recognised that the parents needed time to
discuss their concerns and to have answers to their questions.
She spent the consultation listening to the story of admissions
and on-going symptoms, and explained why there was
uncertainty about the diagnosis and why the treatments that
had been tried had not relieved all the symptoms. She
arranged for the parents to meet with a specialist nurse who
had expertise in managing pre-school children with asthma.
At the review, the nurse was able to reinforce the information
provided by the doctor, review (self) management strategies,
offer practical advice on delivery of inhaled therapy, and
discuss reducing environmental triggers (including offering
the father support with smoking cessation). At a follow-up
appointment a month later, although their son continued to
have occasional symptoms he was still thriving, and the
parents decided against another trial of ICS at this time. The
parents felt reassured and supported, and the decision about
a referral to a hospital clinic was postponed
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